- $60.19m
- -$188.12m
- $52.30m
- 26
- 63
- 44
- 40
Annual income statement for Metagenomi, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0.243 | 17.2 | 44.8 | 52.3 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Total Operating Expenses | 24.2 | 61.8 | 123 | 141 |
| Operating Profit | -23.9 | -44.6 | -78.5 | -88.9 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -21.4 | -41 | -60.2 | -83.6 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -21.4 | -43.6 | -68.3 | -78.1 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -21.4 | -43.6 | -68.3 | -78.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -21.4 | -43.6 | -68.3 | -78.1 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.571 | -1.16 | -1.82 | -2.36 |
| Dividends per Share |